Recently, AHB successfully underwent an unannounced inspection by the U.S. Food and Drug Administration (FDA), achieving a flawless result with "zero deficiencies." This marks the company’s first on-site FDA review, signifying that its food safety management system, production standards, and quality control have reached international high standards, laying a solid foundation for its globalization strategy.
The inspection was part of the U.S. FDA’s Office of Global Policy and Strategy (OGPS) China Food Work Plan for the 2025 fiscal year. The review covered critical areas such as preventive controls, human food operational standards, and general food labeling requirements. The FDA inspection team conducted a comprehensive evaluation of AHB's production facilities, operational processes, food safety plan documentation, and hygiene conditions, with a particular focus on products exported to the United States.
After rigorous review, AHB fully complied with all U.S. FDA regulatory requirements across all inspected areas, with no deficiencies identified. This reflects the company’s robust quality control capabilities across the entire supply chain, from raw materials to finished products.
AHB has long focused on the research, development, and production of functional foods and sports nutrition. Its core products, including alanine, valine, and inositol, are widely exported to international markets such as the United States. The company consistently adheres to high standards in building its food safety system, continuously optimizing production processes, and enhancing quality control. It is committed to providing safe, reliable, and efficient products and solutions to global customers.
The "zero deficiencies" result in the FDA unannounced inspection not only serves as high recognition of AHB's quality management system but also strengthens the trust of international clients in the AHB brand and its products. Moving forward, AHB will continue to uphold its development philosophy of "quality first, innovation-driven," deepen its global compliance efforts, and contribute to earning greater recognition and reputation for China’s biomanufacturing brands on the international stage.
